Nurix Therapeutics

Nurix’s Chief Business Officer, Jason Kantor, Ph.D., will share his experience in establishing major strategic partnerships during two panel sessions on Wednesday, October 30th at the 7th Annual TPD & Induced Proximity Summit. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s Chief Medical Officer, Paula OConnor , M.D., will discuss clinical findings from Nurix’s novel first-in-class BTK degrader, NX-5948, for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) at the 7th Annual TPD & Induced Proximity Summit on Wednesday, October 30th, at 9:00 a.m. ET.   Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s Associate Director of Cell Biology & Project Lead, Ya-Wen Lu, Ph.D., will discuss Nurix’s development of novel BRAF degraders to treat solid tumors in a presentation at the 7th Annual TPD & Induced Proximity Summit on Tuesday, October 29th, at 11:30 a.m. ET. Learn more about the presentation and summit details here: https://bit.ly/47wOe7L

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will join fellow CEOs from other leading targeted protein degradation companies to discuss the current landscape in this exciting field and share strategic advice on advancing multiple #TPD programs through discovery and development to enable clinical success. “The CEO Think Tank” panel will take place on Tuesday, October 29th at 9:30 a.m. ET during the 7th Annual TPD & Induced Proximity Summit. Learn more here: https://bit.ly/47wOe7L  

#ICYMI: Nurix’s Chief Medical Officer, Paula OConnor, M.D., had a busy weekend at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) in Prague where she presented exciting new data from Nurix's ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain penetrant BTK degrader, in patients with relapsed/refractory Waldenstrom’s macroglobulinemia demonstrating robust, durable clinical activity.     Read the press release for the details: https://lnkd.in/gVGqun_u #IWWM12

We are delighted to welcome Anil Kapur to our board of directors.   Mr. Kapur brings over 25 years of executive experience in the pharmaceutical and biotech sectors across both U.S. and international markets, where he has driven commercial excellence and led the successful launch of novel drugs in hematology and oncology.   We look forward to Anil’s leadership and insights as we execute on our plan to advance NX-5948 into pivotal clinical testing and prepare for future commercialization. Learn more here: https://bit.ly/4eJV9xe

Today, we shared our financial results for the third quarter ending August 31, 2024, and provided updates on our advancing pipeline in oncology, inflammation, and immunology. Read more here: https://bit.ly/4dJC8cE

Nurix is proud to support the incredible work of Pass the Smile for Ben, a foundation raising critical funds for research into rhabdomyosarcoma, a rare and aggressive childhood cancer. By partnering with this dedicated community, and joining forces directly through our work on team KOODAC, we aim to advance much-needed research and improve treatment options for those affected by this devastating disease. #KOODAC #PassTheSmile #CancerResearch

In 2024, an estimated 300,000 women and 2,800 men will be diagnosed with #breastcancer. At Nurix, we are committed to developing an innovative targeted protein modulation platform to potentially improve the outcomes of those with breast cancer. Learn more: https://bit.ly/3L7kMKK #BreastCancerAwareness 

Nurix’s Senior Vice President and Head of Early Drug Discovery, Christopher Phelps, Ph.D., will discuss screening DNA Binding Proteins with DNA Encoded Libraries (DEL) in a presentation at the 22nd Annual Discovery on Target Conference on Thursday, October 3rd, at 11:45 a.m. ET. Learn more about the conference here: https://bit.ly/3s6XKOj